RxDoctor Payments Data

Joshua Lovell, DO

Neurology · Logan, UTNPI 1942681051

Payments from drug & device makers

$385in general payments, 2019–2025

Across 20 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$75
  • Jazz Pharmaceuticals Inc.$51
  • Novartis$51
  • Biogen$46
  • UCB, Inc.$27
  • MDD US Operations, LLC$25
  • plus $110 from 6 others

What the payments were for

  • Food & beverage$36996%
  • Education$164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$385 in reported general payments places this provider in the 40th percentile of 157 neurology providers in Utah.

See all neurology providers in Utah

Medicare billing

Part B allowed, 2024
$310,156
Medicare patients
289
Services billed
17,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$186,516
CopaxoneGlatiramer Acetate12$80,530
Aimovig AutoinjectorErenumab-Aooe91$71,089
RytaryCarbidopa/Levodopa46$70,749
Nurtec OdtRimegepant Sulfate31$34,917
Emgality PenGalcanezumab-Gnlm42$34,191
Ajovy SyringeFremanezumab-Vfrm29$21,745
UbrelvyUbrogepant21$21,557
Ajovy AutoinjectorFremanezumab-Vfrm26$19,619
QuliptaAtogepant17$18,644
Teriflunomide34$11,392
Emgality SyringeGalcanezumab-Gnlm12$8,309
EliquisApixaban11$6,579
Entacapone26$6,320
Carbidopa-LevodopaCarbidopa/Levodopa201$5,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$22$40,20138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 157 neurology providers in Utah.

Other neurology in Logan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →